Unknown

Dataset Information

Abstract 8 Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematologic Malignancies: Results from a Phase III Randomized, Multicenter Study


ABSTRACT: Abstract

Introduction

Omidubicel, an advanced cell therapy used for allogeneic hematopoietic stem cell transplant has demonstrated faster hematopoietic recovery, shorter hospitalization, and lower rates of bacterial, viral, and invasive fungal infections compared with umbilical cord blood (UCB) in a phase III randomized trial (NCT02730299;Blood 2021;138:1429).

Objective

The objective was to compare changes in health-related quality of life (HRQL) between treatment groups in the phase III trial.

Methods

Patients who received protocol-defined treatment and provided HRQL evaluations at baseline and ≥1 follow-up visit were analyzed. Outcomes included Functional Assessment of Cancer Therapy General (FACT-G) domain scores for physical, social/family, functional and emo

SUBMITTER:  

PROVIDER: S-EPMC9446902 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature